These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 36515370)

  • 21. Magic Mushrooms - an exploratory look at how mental health professionals feel and think about Psilocybin.
    Meyer TD; Meir P; Lex C; Soares JC
    Psychiatry Res; 2022 Oct; 316():114727. PubMed ID: 35878481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing potential of psilocybin for depressive disorders.
    Kozak Z; Johnson MW; Aaronson ST
    Expert Opin Investig Drugs; 2023; 32(10):887-900. PubMed ID: 37869790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
    Davis AK; Barrett FS; May DG; Cosimano MP; Sepeda ND; Johnson MW; Finan PH; Griffiths RR
    JAMA Psychiatry; 2021 May; 78(5):481-489. PubMed ID: 33146667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An episode of mania following self-reported ingestion of psilocybin mushrooms in a woman previously not diagnosed with bipolar disorder: A case report.
    Hendin HM; Penn AD
    Bipolar Disord; 2021 Nov; 23(7):733-735. PubMed ID: 33934465
    [No Abstract]   [Full Text] [Related]  

  • 25. Content analysis of Reddit posts about coadministration of selective serotonin reuptake inhibitors and psilocybin mushrooms.
    Sakai K; Bradley ER; Zamaria JA; Agin-Liebes G; Kelley DP; Fish A; Martini V; Ferris MC; Morton E; Michalak EE; O'Donovan A; Woolley JD
    Psychopharmacology (Berl); 2024 Aug; 241(8):1617-1630. PubMed ID: 38687360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Psilocybin history, action and reaction: A narrative clinical review.
    Sharma P; Nguyen QA; Matthews SJ; Carpenter E; Mathews DB; Patten CA; Hammond CJ
    J Psychopharmacol; 2023 Sep; 37(9):849-865. PubMed ID: 37650489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The impact of psilocybin on visual perception and spatial orientation--neuropsychological approach].
    Jastrzebski M; Bala A
    Psychiatr Pol; 2013; 47(6):1157-67. PubMed ID: 25007546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health Benefits and Positive Acute Effects of Psilocybin Consumption: A Quantitative Textual Analysis of User Self-Reported Data.
    Bienemann B; Barbosa AR; Cruz LVMD; Multedo M; Mograbi D
    J Psychoactive Drugs; 2024; 56(3):324-332. PubMed ID: 37348116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential use of psilocybin drugs in the treatment of depression.
    Śladowska K; Kawalec P; Brzostek T; Pilc A
    Expert Opin Emerg Drugs; 2023 Dec; 28(4):241-256. PubMed ID: 37817501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The pharmacology of psilocybin.
    Passie T; Seifert J; Schneider U; Emrich HM
    Addict Biol; 2002 Oct; 7(4):357-64. PubMed ID: 14578010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Manic episode following psilocybin use in a man with bipolar II disorder: a case report.
    Halim HJ; Burk BG; Fargason RE; Birur B
    Front Psychiatry; 2023; 14():1221131. PubMed ID: 37810598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.
    Griffiths RR; Hurwitz ES; Davis AK; Johnson MW; Jesse R
    PLoS One; 2019; 14(4):e0214377. PubMed ID: 31013281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DARK Classics in Chemical Neuroscience: Psilocybin.
    Geiger HA; Wurst MG; Daniels RN
    ACS Chem Neurosci; 2018 Oct; 9(10):2438-2447. PubMed ID: 29956917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Between prohibitions: patterns and meanings of magic mushroom use in the UK.
    Riley SC; Blackman G
    Subst Use Misuse; 2008; 43(1):55-71. PubMed ID: 18189205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research.
    Bender D; Hellerstein DJ
    Psychopharmacology (Berl); 2022 Jun; 239(6):1907-1932. PubMed ID: 35022823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
    Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
    J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.
    Rosenbaum D; Weissman C; Anderson T; Petranker R; Dinh-Williams LA; Hui K; Hapke E
    J Psychopharmacol; 2020 Jun; 34(6):612-622. PubMed ID: 32108529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy.
    de la Salle S; Kettner H; Thibault Lévesque J; Garel N; Dames S; Patchett-Marble R; Rej S; Gloeckler S; Erritzoe D; Carhart-Harris R; Greenway KT
    Sci Rep; 2024 Jul; 14(1):16524. PubMed ID: 39019922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A survey of hallucinogenic mushroom use, factors related to usage, and perceptions of use among college students.
    Hallock RM; Dean A; Knecht ZA; Spencer J; Taverna EC
    Drug Alcohol Depend; 2013 Jun; 130(1-3):245-8. PubMed ID: 23265089
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Hallucinogenic mushrooms].
    Reingardiene D; Vilcinskaite J; Lazauskas R
    Medicina (Kaunas); 2005; 41(12):1067-70. PubMed ID: 16401965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.